You are in the first product of the category

Bladder Cancer Epidemiology Forecast

$ 6.690,00

Bladder Cancer Epidemiology Forecast

The bladder cancer is the second most common urologic cancer, this disease is classified as ICD-9-CM category 188. In the G7 mature markets (the USA, Japan, France, Germany, Italy, Spain, the UK), Hoffmann-Krueger epidemiologists expect the incident cases of bladder cancer to increase from 189 956 cases in 2012 to 237 195 cases in 2022.

  • Countries concerned :

Add to my wishlist

Scope

G7 Mature markets (the USA, Japan, France, Germany, Italy, Spain, the UK) 10-year patient population forecast + 5 years of historical data

 

Key Users 

Oncology Market Research - New Product Planning - Business Development & Licensing - Oncology Market Access – Oncology Marketing leaders.

 

Insight 

Insight into the bladder cancer strategy and business development activities. Transparent forecasts methodology and assumptions. Concise and comparable analysis

Key epidemiology assumptions are included to give accurate sizing of patient population, epidemiology forecast, key drivers of patient shares.The oncology drug market is one of the fastest-growing markets in the pharmaceutical industry. The treatment of cancer has shifted away from mass market blockbuster drugs toward a more focused attack on the disease with targeted therapies.

 

Reasons To Buy

Hoffmann-Krueger  ECF (Epidemiology Cancer Forecast) rich data set and easy-to-use tool  allow you to focus on cancer subpopulation segment of interest. Hoffmann-Krueger  ECF (Epidemiology Cancer Forecast) giving the opportunity to use epidemiological projections of key oncology patient population.

  • Country : France | United Kingdom | Japan | Germany | United States | Spain | Italy
  • Cancer Type : Urinary Bladder
  • File : xls